EVOK Evoke Pharma, Inc.

0  -1%
Previous Close 2.74
Open 2.76
Price To book 8.90
Market Cap 33.35M
Shares 12,305,000
Volume 122,913
Short Ratio 0.76
Av. Daily Volume 786,447

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint not met. However, the company noted December 15, 2016 that following discussions with FDA regarding possible NDA submission, no new efficacy or safety study would be required, if bioequivalence criteria were met in a pharmacokinetic (PK) trial. Confirmed April 4, 2017 that PK data will be released 2H 2017 with NDA filing to be submitted by late 2017 or early 2018.
Gimoti - EVK-001
Female diabetic gastroparesis

Latest News

  1. Evoke Pharma Announces Collaboration with Spaulding Clinical Research for the Gimoti Comparative Exposure Pharmacokinetic Trial
  2. Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma’s Proposed Comparative Exposure PK Trial for Gimoti NDA
  3. Evoke Pharma’s Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017
  4. Evoke Pharma Reports Fourth Quarter and Full Year 2016 Results
  5. Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results
  6. Evoke Pharma Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
  7. Biotech Industry Poised for a Breakout in 2017? Today's Reports on Evoke Pharma and Novavax
  8. Evoke Pharma Announces Pricing of Public Offering of Common Stock
  9. Evoke Pharma Announces Proposed Public Offering of Common Stock
  10. Why Evoke Pharma Shares Are Exploding
  11. Evoke Pharma's stock soars after FDA exempts Gimoti from HF Validation
  12. FDA Exempts Evoke from Requirement for Human Factor Validation Study
  13. Biotech Acquisitions on the Rise in 2017: Latest Reports on Calithera Biosciences and Evoke Pharma
  14. Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
  15. Wednesday’s Top 5 Biopharma Movers
  16. Here’s What’s Next For Evoke Pharma Inc (EVOK)
  17. Company News for December 19, 2016
  18. Latest Reports on Biotech Movers Evoke Pharma and Cytori Therapeutics

SEC Filings

  1. 8-K - Current report 17766075
  2. 8-K - Current report 17736268
  3. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17705736
  4. DEF 14A - Other definitive proxy statements 17705734
  5. 8-K - Current report 17703070
  6. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17691402
  7. 8-K - Current report 17691356
  8. 8-K - Current report 17683092
  9. 424B5 - Prospectus (Rule 424(b)(5)) 17683072
  10. 424B5 - Prospectus (Rule 424(b)(5)) 17618123